Perrigo Rogaine foam ANDA draws suit
This article was originally published in The Tan Sheet
Executive Summary
The Allegan, Mich., private labeler reports Oct. 13 it is the first to file an abbreviated new drug application for minoxidil topical aerosol foam, 5 percent, equivalent to Johnson & Johnson's hair re-growth OTC Men's Rogaine Foam. Patent holder and GlaxoSmithKline subsidiary Stiefel filed an infringement suit Oct. 9 against the private-label firm, initiating a 30-month stay against generic competition under the Hatch-Waxman Act. Perrigo said the branded version generates about $52 million in annual sales. Patents for Rogaine Foam, launched in 2006 by Pfizer, run through 2019. While Stiefel owns the Rogaine Foam patent, J&J holds the NDA (1"The Tan Sheet" Sept. 11, 2006)
You may also be interested in...
Rogaine Foam Patents To Keep Product Covered Through 2019, Pfizer Says
Pfizer Consumer Healthcare's new foam delivery form ofRogaine (minoxidil) carries three years of marketing exclusivity and is patent-protected through 2019, the firm announced Sept. 5
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.